SCHEMBL23218485

SCHEMBL23218485

CCOC(=O)Cc1ccccc1OCc1coc2c(OCc3ccccn3)cc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.40
SLC1A5 Q15758 1/20 0.38
ABCB1 P08183 2/20 0.37
HTR1A P08908 2/20 0.37
DRD2 P14416 2/20 0.37
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CFD P00746 1/20 0.36
SYK P43405 4/20 0.35
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
PTGER1 P34995 1/20 0.35
HPGD P15428 2/20 0.35
CASP3 P42574 2/20 0.35
SENP8 Q96LD8 2/20 0.35
SENP7 Q9BQF6 2/20 0.35
SENP6 Q9GZR1 2/20 0.35
AURKB Q96GD4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852558 1.00 TBXAS1 (0.40) TBXAS1SLC1A5ABCB1HTR1ADRD2
SCHEMBL23218656 0.89 PTGER1 (0.40) TBXAS1TDP1CFDMAPTTP53
SCHEMBL29852614 0.89 PTGER1 (0.40) TBXAS1TDP1CFDMAPTTP53
SCHEMBL29852821 0.88 PIM1 (0.44) TBXAS1ABCB1CFDMAPTPTGER1
SCHEMBL23218270 0.88 PIM1 (0.44) TBXAS1ABCB1CFDMAPTPTGER1
SCHEMBL23218305 0.86 TBXAS1 (0.42) TBXAS1CFDMAPTTP53THRB
SCHEMBL29852692 0.86 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL23218101 0.86 TBXAS1 (0.39) TBXAS1CFDMAPTTP53THRB
SCHEMBL23218928 0.86 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB
SCHEMBL29853232 0.86 TBXAS1 (0.41) TBXAS1CFDMAPTTP53THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-07-18 US disclosed
CN-117120419-A KLK5 bicyclic heteroaromatic inhibitors 拜奥克里斯特制药公司 2023-11-24 CN disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239752-A1 BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 KLK5, KLK1, KLKB1 TBXAS1 2084/4885SLC1A5 2172/4885ABCB1 884/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885SLC1A5 1867/4885ABCB1 798/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885SLC1A5 3464/4885ABCB1 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.